PCSK9 and inherited lipid metabolism disorder: It is not clear what proportion of patients this would apply to, but it was estimated in the US in 2019 that PCSK9 inhibitors were used in <1% of patients with either dyslipidaemia (including familial hypercholesterolaemia), elevated LDL-C (≥130 mg/dL [3.4 mmol/L]), or pre-existing CHD.28